{'52WeekChange': 0.5784062,
 'SandP52WeekChange': 0.0644362,
 'address1': '230 Park Avenue',
 'address2': 'Suite 3350',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 46.25,
 'askSize': 900,
 'averageDailyVolume10Day': 170137,
 'averageVolume': 251038,
 'averageVolume10days': 170137,
 'beta': None,
 'beta3Year': None,
 'bid': 31.03,
 'bidSize': 900,
 'bookValue': 4.41,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 38.43,
 'dayLow': 36.64,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -13.735,
 'enterpriseToRevenue': None,
 'enterpriseValue': 1280987776,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 42.906284,
 'fiftyTwoWeekHigh': 50.49,
 'fiftyTwoWeekLow': 14.16,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 18169631,
 'forwardEps': -1.06,
 'forwardPE': -34.75472,
 'fromCurrency': None,
 'fullTimeEmployees': 65,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.37469003,
 'heldPercentInstitutions': 0.53004,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/ymabs.com',
 'longBusinessSummary': 'Y-mAbs Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on the development '
                        'and commercialization of novel antibody-based '
                        'therapeutic products for the treatment cancer in the '
                        'United States. The company develops naxitamab that is '
                        'in Phase 2 clinical trial for the treatment of '
                        'pediatric patients with relapsed steosarcoma or '
                        'refractory, and high-risk neuroblastoma, as well as '
                        'other GD2 positive tumors; and GD2-GD3 Vaccine which '
                        'is in Phase 2 clinical trial for the treatment of '
                        'high-risk neuroblastoma. It is developing omburtamab '
                        'that is in Phase 2 clinical trial for the treatment '
                        'of desmoplastic small round cell tumors; in Phase 1 '
                        'clinical trial for the treatment of diffuse intrinsic '
                        'pontine glioma, as well as for the treatment of '
                        'pediatric patients with central nervous system and '
                        'leptomeningeal metastases; The company also engages '
                        'in the development of huB7-H3 product candidate for '
                        'the treatment of B7-H3 positive adult solid tumors; '
                        'and pre clinical development of huCD33 BsAb product '
                        'candidate for the treatment of huCD33 positive '
                        'hermatological cancers. The company has a license and '
                        'research collaboration agreement with Memorial Sloan '
                        'Kettering Cancer Center and Massachusetts Institute '
                        'of Technology to develop and commercialize antibody '
                        'constructs based on the SADA-BiDE pre-targeted '
                        'radioimmunotherapy platform. Y-mAbs Therapeutics, '
                        'Inc. was founded in 2015 and is headquartered in New '
                        'York, New York.',
 'longName': 'Y-mAbs Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 1464669952,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_378585331',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -91273000,
 'nextFiscalYearEnd': 1640908800,
 'open': 37.94,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.12,
 'phone': '646 885 8505',
 'previousClose': 38.19,
 'priceHint': 2,
 'priceToBook': 8.353742,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 38.43,
 'regularMarketDayLow': 36.64,
 'regularMarketOpen': 37.94,
 'regularMarketPreviousClose': 38.19,
 'regularMarketPrice': 37.94,
 'regularMarketVolume': 112260,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 39757600,
 'sharesPercentSharesOut': 0.063,
 'sharesShort': 2506618,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2126593,
 'shortName': 'Y-mAbs Therapeutics, Inc.',
 'shortPercentOfFloat': 0.0845,
 'shortRatio': 8.18,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'YMAB',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.496,
 'twoHundredDayAverage': 34.323742,
 'volume': 112260,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.ymabs.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10169'}